Transaction · 0001628280-26-005567

Welgus Howard G.

Welgus Howard G., DIR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 10000.000000 shares for an estimated $250483.00. Reported holdings after the transaction were 59744.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
ARQTArcutis Biotherapeutics, Inc.
Filing timeFeb 05
Trade dateFeb 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$26.07
Pre-filing
1mo ago +11.2%1w ago +1.0%1d ago -2.7%
Returns since
7d +2.5%30d -7.9%90d -7.3%180d -0.2%1y -8.8%

ARQT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARQT since 2026-02-05Filed 210 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001628280-26-005567
Common Stock
Transaction date
Feb 02, 2026
Filed Feb 05, 2026, 12:23 AM · 3d delay
Shares
10.0k sh
$2.50k per share
Estimated value
-$25.0M
Computed from shares × price
Holdings after
59.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

  2. F2

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive. The Reporting Person hereby undertake…

Original filing · 0001628280-26-005567
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARQT